ANNOUNCEMENT

NOBEL PRIZE 2026

This year's laureates, their fields, and the discoveries that earned them the prize.Live nowSee the winners
Moonbase
← Back to Awards
NIHNATIONAL INSTITUTE ON AGING

Selective vulnerability and resilience to trans-synaptic pathological tau spreading in Alzheimers disease

Completed
Institution
UNIVERSITY OF TEXAS MED BR GALVESTON, TX
Principal investigator
Giulio Taglialatela
Funding
$200K
Duration
2024–2026
Open portfolio

Moonbase score

Still being scored

Abstract

PROJECT SUMMARY The incidence of Alzheimer’s disease (AD) is on the rise, and we are in dire need of effective treatments. In AD, the spatiotemporal progression of tau pathology within the CNS remains the strongest neuropathological correlate of cognitive impairment, thus constituting a likely effective treatment target ( long- term goal). Compelling evidence supports a trans-synaptic framework for pathological tau spreading, driven primarily by the propagation of toxic soluble tau oligomer (tauO) conformers between functionally connected brain regions. Numerous investigations further postulate the influence of amyloid-beta (Aβ) on trans- neuronal pathological tau spreading, while emerging evaluations of primary tauopathies (e.g. Primary Age Related Tauopathy—PART), which lack Aβ, observe limited regional tau spreading alongside little-to-no amnestic changes. Within the trans-synaptic spreading framework, however, the precise mechanisms by which tauO selectively engage key synaptic subtypes (e.g. excitatory vs. inhibitory), and the role of Aβ in this process, remain unknown. We thus hypothesize that Aβ modulates pathological tau spreading by increasing oligomeric tau binding and internalization to vulnerable synapses. To support this hypothesis, we provide novel preliminary evidence for increased binding and internalization of toxic tauO binding in the presence of soluble Aβ oligomers in human synapses. In Aim 1, we will determine the role of AβO in modulating synaptic tauO binding within a framework of cellular, regional and clinical resilience to pathological tau burden. In Aim 2, we will determine key synaptic proteins that modulate the binding and/or internalization of tauO in the presence and absence of AβO. To execute these aims, we have developed an innovative and translationally relevant approach to interrogate mechanisms of tau binding directly in human synapses isolated from post-mortem autopsy specimen using an array of biochemical techniques. At the completion of this project, we expect to document previously unappreciated mechanisms that modulate synaptic tauO binding and internalization—a key component of pathological tau spreading.

LOADING MOONBASE SCORE

NATIONAL INSTITUTE ON AGINGR21Special Emphasis Panel[ZRG1-AN-Q(55)]spreadinginternalizationpathologicalsynapsesbindingsynaptictaupathological tau

Questions for UNIVERSITY OF TEXAS MED BR GALVESTON

Answered by the team behind this research.

Same researchers, same institution, same topic, scored first.